OraSure Technologies Rating Increased to Outperform at Zacks (OSUR)
OraSure Technologies (NASDAQ:OSUR) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a research note issued on Tuesday. The firm currently has a $9.20 price target on the stock. Zacks‘s target price points to a potential upside of 6.73% from the company’s current price.
Shares of OraSure Technologies (NASDAQ:OSUR) traded down 2.20% on Tuesday, hitting $8.43. The stock had a trading volume of 463,695 shares. OraSure Technologies has a 52 week low of $3.75 and a 52 week high of $9.00. The stock’s 50-day moving average is $6.86 and its 200-day moving average is $6.80. The company’s market cap is $470.7 million.
OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.10) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.13) by $0.03. The company had revenue of $23.50 million for the quarter, compared to the consensus estimate of $23.28 million. During the same quarter last year, the company posted ($0.18) earnings per share. OraSure Technologies’s revenue was up 10.8% compared to the same quarter last year. Analysts expect that OraSure Technologies will post $-0.22 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Jefferies Group reiterated a “buy” rating on shares of OraSure Technologies in a research note on Thursday, June 12th. They now have a $10.00 price target on the stock, up previously from $9.00. Separately, analysts at Raymond James raised their price target on shares of OraSure Technologies from $8.50 to $9.00 in a research note on Thursday, June 12th. Finally, analysts at Canaccord Genuity raised their price target on shares of OraSure Technologies from $10.00 to $11.00 in a research note on Thursday, June 12th. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $9.70.
OraSure Technologies, Inc, is engaged in development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using the Company’s oral fluid technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.